Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
Holding AVDL?
Track your performance easily
See the Price Targets and Ratings of:
AVDL Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AVDL Stock 12 Month Forecast
Average Price Target
$24.60
▲(110.98% Upside)
| Highest Price Target$30.00 | Average Price Target$24.60 | Lowest Price Target$20.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Craig-Hallum
Assigned
11/13/24
H.C. Wainwright
Reiterated
11/13/24
Leerink Partners
Reiterated
11/12/24
Oppenheimer
Reiterated
10/31/24
Ladenburg Thalmann & Co.
Reiterated
08/09/24
Rodman & Renshaw
$27
Buy
131.56%
Upside
Initiated
06/11/24
Rodman & Renshaw starts Avadel with Buy on promising Lumryz launchRodman & Renshaw starts Avadel with Buy on promising Lumryz launch
Piper Sandler
$18→$23
Buy
97.26%
Upside
Reiterated
03/04/24
Avadel Pharmaceuticals (AVDL) PT Raised to $23 at Piper SandlerPiper Sandler analyst David Amsellem raised the price target on Avadel Pharmaceuticals (NASDAQ: AVDL) to $23.00 (from $18.00) while maintaining a Overweight rating.
―
LifeSci Capital
―
Buy
―
Reiterated
11/12/24
Avadel Pharmaceucals (Nasdaq: AVDL) management reported $50.0M and in net revenue for Lumryz in the third quarter 2024. The results beat revenue consensus for the quarter which stood at $48.6. We are encouraged by the connued progress nong that more than 2,300 paents are on therapy, up 500 paents from the latest update in 700 paents that iniated therapy in the third quarter. We are pleased to see clear signs that the approval of Lumryz has indeed expanded the market with paents on therapy coming from all three paent segments and prescripons including 150 HCP who are new to oxybate, up from 100 last quarter. We expect these trends to connue into 2025 as Lumryz gains more market share.
Best Analysts Covering Avadel Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy AVDL and Sell After:
1 Month
xxx
Success Rate
14/25 ratings generated profit
Average Return
+6.72%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.00% of your transactions generating a profit, with an average return of +6.72% per trade.
3 Months
xxx
Success Rate
15/25 ratings generated profit
Average Return
+12.52%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +12.52% per trade.
1 Year
2 Years
xxx
Success Rate
17/25 ratings generated profit
Average Return
+73.32%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.00% of your transactions generating a profit, with an average return of +73.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AVDL Analyst Recommendation Trends
Rating
Jun 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
5
11
8
12
10
Buy
3
8
6
8
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
19
14
20
13
Each month's total comprises the sum of three months' worth of ratings.
AVDL Financial Forecast
AVDL Stock Forecast FAQ
What is AVDL’s average 12-month price target, according to analysts?
Based on analyst ratings, Avadel Pharmaceuticals’s 12-month average price target is $24.60.
What is AVDL’s upside potential, based on the analysts’ average price target?
Avadel Pharmaceuticals has 110.98% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AVDL a Buy, Sell or Hold?
Avadel Pharmaceuticals has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Avadel Pharmaceuticals’s price target?
The average price target for Avadel Pharmaceuticals is $24.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $20.00. The average price target represents 110.98% Increase from the current price of $11.66.
The highest analyst price target is $30.00 ,the lowest forecast is $20.00. The average price target represents 110.98% Increase from the current price of $11.66.
What do analysts say about Avadel Pharmaceuticals?
Avadel Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of AVDL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.